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Abstract 
Background: In Ghana, malaria is endemic and perennial (with significant seasonal variations in the three North-
ern Regions), accounting for 33 % of all deaths among children under 5 years old, with prevalence rates in children 
under-five ranging from 11 % in Greater Accra to 40 % in Northern Region. Ghana adopted the WHO-recommended 
Seasonal Malaria Chemoprevention (SMC) strategy with a trial in the Upper West Region in 2015. The objective of this 
study was to estimate the cost-effectiveness of seasonal malaria chemoprevention.
Methods: Costs were analysed from provider and societal perspectives and are reported in 2015 US$. Data on 
resource use (direct and indirect costs) of the SMC intervention were collected from intervention records and a survey 
in all districts and at regional level. Additional numbers of malaria cases and deaths averted by the intervention were 
estimated based on prevalence data obtained from an SMC effectiveness study in the region. Incremental cost-
effectiveness ratios (ICERs) were estimated for the districts and region. Sensitivity analyses were conducted to test the 
robustness of the ICERs.
Results: The total financial cost of the intervention was US$1,142,040.80. The total economic cost was estimated to 
be US$7.96 million and US$2.66 million from the societal and provider perspectives, respectively. The additional num-
bers of cases estimated to be averted by the intervention were 24,881 and 808, respectively. The economic cost per 
child dosed was US$67.35 from societal perspective and US$22.53 from the provider perspective. The economic cost 
per additional case averted was US$107.06 from the provider perspective and US$319.96 from the societal perspec-
tive. The economic cost per additional child death averted by the intervention was US$3298.36 from the provider 
perspective and US$9858.02 from the societal perspective. The financial cost per the SMC intervention delivered to a 
child under-five was US$9.66. The ICERs were sensitive to mortality rate used.
Conclusions: The SMC intervention is economically beneficial in reducing morbidity in children under-5 years and 
presents a viable approach to improving under-five health in Ghana.
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Background
The global burden of malaria reduced by about 18  % at 
2015 (from 262 million in 2000 to 214 million in 2015) 
according to recent World Health Organization (WHO) 
estimates [1]. During the same period, malaria incidence, 
mortality rate and deaths were estimated to have fallen 
by 37, 60 and 48  %, respectively. In spite of the major 
achievements in the fight against malaria, the disease 
continues to pose a major public health challenge, espe-
cially in sub-Saharan Africa (SSA), which accounted for 
about 88 % of the global cases and 90 % of deaths in 2015 
[1]. Deaths in children under-5 years old in SSA reduced 
by about 57.9  %, moving malaria from the leading to 
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the fourth cause of death in under-fives in Africa. Thus, 
malaria accounted for about 10 % of under-five deaths in 
SSA in 2015 [1].
In Ghana, malaria has consistently remained the lead-
ing cause of morbidity and mortality accounting for 
about 38 % of all outpatient visits and 27.3 % of all admis-
sions and responsible for 48.5 % of all deaths among chil-
dren below age 5  years in 2015 [2]. Malaria prevalence 
rates in children under-five ranges from 11 % in Greater 
Accra to 40 % in Northern Region [3]. Ghana was one of 
the ten African countries that accounted for more than 
60 % of malaria deaths in SSA in 2012 [4].
Despite the many interventions in place, it appears 
the burden of malaria remains high and new preventive/
control measures are of necessity to augment the exist-
ing measures. Seasonal malaria chemoprevention (SMC), 
formerly known as intermittent preventive treatment 
in children (IPTc), has been identified as an effective 
strategy in areas with a short malaria transmission sea-
son. For example, in a systematic review/meta-analysis 
of SMC studies, Wilson [5] showed that giving children 
under-5  years of age sulfadoxine–pyrimethamine plus 
amodiaquine (SP-AQ) once per month during the peak 
malaria transmission season reduced the incidence of 
clinical attacks of malaria by 83 % and severe malaria by 
77  %. Further, a Cochrane review by Meremikwu et  al. 
[6] reported the SP-AQ combination therapy as safe. 
SMC is a community-level intervention and the use 
of community health workers for implementation has 
proven to increase coverage and cost effectiveness [7, 8]. 
The administration of SMC medicines is usually done 
monthly for 3–4 months during the peak malaria trans-
mission season.
Against this background, the WHO in 2011 [9] recom-
mended incorporation of SMC into malaria control pro-
grammes in areas with highly seasonal transmission of 
malaria. By 2014, six countries in SSA (Chad, The Gam-
bia, Guinea, Mali, Niger, and Senegal), had adopted the 
SMC strategy, with two others (Togo and Congo) report-
ing policy to adopt it. Ghana started implementation in 
2015.
Ghana can be stratified roughly into three malaria epi-
demiologic zones: northern savannah, tropical rainforest, 
and coastal savannah/mangrove swamps. The length of 
malaria transmission season varies by geographic region. 
There are two major transmission patterns. In the north-
ern part of the country, there is a 6- to 7-month transmis-
sion season, with the highest number (50–60 %) of cases 
occurring between July and November. In the south-
ern part of the country, malaria is endemic through-
out the year with some heightened transmission during 
May to June and a larger peak in October to November. 
Malaria prevalence and seasonality makes Ghana, and 
its northern regions in particular, an excellent choice for 
implementing the SMC intervention [10]. Ghana piloted 
SMC intervention in July to October 2015, with a trial 
in the Upper West Region (which has one of the highest 
prevalence of malaria in the country—37.8  %) through 
support from the Department for International Devel-
opment of the UK (DFID) and the Global Fund. Lessons 
learnt from this implementation were to be used in scal-
ing up SMC in other eligible northern regions of Ghana. 
The intervention used the services of volunteers super-
vised by district and sub-district health workers.
Studies have shown that different delivery models of 
various malaria control strategies are cost-effective (i.e., 
represent a good use of society’s resources). For instance, 
insecticide-treated net (ITN) campaigns are cost-effec-
tive in reducing morbidity and mortality in children in 
Ghana [11, 12], Uganda [13], Tanzania [14–16], and Togo 
[17]. Further, indoor residual spraying (IRS) has been 
shown to be a cost-effective malaria vector control strat-
egy in Mozambique [18, 19], Kenya [20], South Africa 
[19], and SSA [21]. Conteh et al. [22], Conteh et al. [23] 
and Ross et al. [8] present the cost-effectiveness of differ-
ent strategies for delivering intermittent preventive treat-
ments in children and infants. Again, there is evidence 
that malaria diagnostic and treatment strategies present 
value-for-money to society. These studies and others 
have shown that the WHO-recommended approach of 
using trained community health volunteers to diagnose 
and treat uncomplicated fevers (including malaria) in 
children near their home is cost-effective (Ghana [24]; 
Uganda [25]; Zambia [26]).
Although IPTc has been shown to be cost-effective 
elsewhere [8, 22] and in Ghana [23], there is paucity of 
studies assessing the cost-effectiveness of SMC in its cur-
rent approach (and using the combination of anti-malar-
ials) as recommended by the WHO in 2012. The focus of 
the study by Conteh et al. [23] was on delivery strategies 
of IPTc using SP or AS (Artesunate)–AQ, whereas SMC 
uses SP plus AQ. Thus, it is important to assess the cost-
effectiveness of SMC in the Ghanaian context to inform 
scale-up. The findings of this study will be useful for 
Ghana and other SSA countries that are in the process 
of scaling-up or implementing SMC as recommended by 
WHO.
The aim of this study was to estimate the cost-effec-
tiveness of SMC intervention delivered to children 
under-5 years old in the Upper West Region of Ghana.
Methods
SMC intervention
Following WHO recommendations on administration of 
SMC to children under-5 years, all eligible children were 
given full treatment doses of sulfadoxine–pyrimethamine 
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(SP) and amodiaquine (AQ) at monthly intervals from 
mid-June to mid-September 2015. Each child was given 
four courses of the treatment (i.e., a fully dosed child). 
Dosing schedules are shown in Fig. 1.
The recommended anti-malarials (AQ-SP) were 
administered to each child as directly observed therapy 
as scheduled in each cycle. There were 3 days for dosing 
children and 2 days for follow-up on pharmaco-vigilance 
per cycle. Volunteers visited each household and the tar-
get children were given the required number of doses 
of the anti-malarial as scheduled. An active pharmaco-
vigilance system was established to capture adverse drug 
reactions (ADR) in children who received SMC in each 
intervention district. This was done following the guide-
line outlined under reporting of adverse events (i.e., mild, 
moderate, severe, and life-threatening). The intervention 
was carried out in four rounds in all 11 districts: Round 1 
was from 20–29 July; Round 2 was from 24–29 August; 





Infants 3–11 months: Single 
dose of half a 500/25mg tablet; 
Children 12–59 months:
Single dose of a full tablet of 
500/25mg 
Amodiaquine (AQ): 
Infants 3–11 months: Single 
dose of half a 153mg tablet;
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Fig. 1 Algorithm for seasonal malaria chemoprevention (SMC)
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Study setting
The study was conducted in the Upper West Region of 
Ghana, located in northwestern Ghana. It is bordered 
to the south by the Northern Region, to the north and 
west by Burkina Faso and to the east by the Upper East 
region. With an area of 18,476 sq km, the region’s popu-
lation density stands at 40 persons per sq km. The pro-
jected population for 2015 based on the 2010 Population 
and Housing Census growth rate of 1.9 % is 771,394. The 
climate is tropical with an average minimum tempera-
ture of 22.6 °C and maximum of 40.0 °C. There are two 
main seasons: the rainy season begins around April and 
ends in October with peaks in July, August and Septem-
ber. The dry season commences in late November to the 
end of April. The dry season is characterized by harsh 
climatic conditions of dryness, high temperatures and 
dust. The Region has been divided into 11 administrative 
districts, which correspond to the division of the health 
sector.
The Regional Health Management Team (RHMT) 
oversees planning and implementation of health services 
in the Region. There are 11 district health management 
teams (DHMT) with 66 sub-districts. There is a total of 
249 health facilities in the region: one regional hospi-
tal, three district government hospitals, three private 
hospitals and two mission hospitals, five policlinics, 65 
health centres, 14 clinics, five maternity homes, and 194 
community-based health planning and services (CHPS) 
compounds. Health services such as clinical care, repro-
ductive and child health, nutrition, immunization, and 
other disease control services are delivered in all the 
districts with support from a community-based health 
system of volunteers and service providers, made up of 
1209 traditional birth attendants, 1850 community-based 
surveillance volunteers, 3520 community-based agents, 
and 184 guinea worm volunteers who are providing vari-
ous services in 3557 demarcated areas, with supervision 
from sub-district health staff. There are also 861 out-
reach points for the provision of immunization and other 
services.
Study population and sampling
The study population for the SMC intervention was chil-
dren between age 3 and 59  months in all 11 districts. 
Given the nature of the study, which involved use of com-
munity volunteers and participation of caregivers, the 
sampling procedure involved selection of volunteers and 
caregivers from all 11 districts.
In each district, two sub-districts were randomly 
selected. Sub-district supervisors, mainly health work-
ers in the sub-district, then identified the volunteers they 
supervised, and these volunteers were interviewed. Sub-
sequently, each volunteer interviewed led the research 
team to interview caregivers whose children were 
dosed by the volunteers. The caregivers were also inter-
viewed. In all, 112 volunteers and 517 caregivers were 
interviewed.
SMC effectiveness study
The intervention was implemented in all 11 districts 
of the Upper West Region. However, an effective-
ness study was undertaken to ascertain the impact of 
SMC on malaria morbidity and mortality in children 
under-5  years using a cluster-randomized comparative 
study design with one district randomly selected in the 
intervention area and another in the Northern Region (a 
control region) where SMC was not implemented. The 
Northern Region is similar to the Upper West Region 
in terms of malaria transmission and other social infra-
structure, such as the health service delivery system. 
Most childhood mortality and morbidity from malaria 
occurs during the rainy season. The intervention dis-
trict selected was Lawra District (upper west region) and 
the control district West Mamprusi District (northern 
region). The estimated prevalence in this case–control 
study was used to estimate the caseload with and without 
SMC in the study area.
Data collection
Both financial and economic costs were measured. Finan-
cial costs were actual expenditure incurred in undertak-
ing the SMC intervention, whilst economic costs were 
broader and dealt with opportunity cost (alternative use) 
of using the resources in the intervention (i.e., direct and 
indirect costs to both volunteers and caregivers were 
incorporated). Estimated financial costs were useful for 
developing the budget for scale-up and the economic 
costs were used for estimating the cost-effectiveness of 
the intervention. An ingredient approach was used to 
identify all resources required to implement the SMC 
dosing programme throughout the region. Financial 
costs were obtained retrospectively from the SMC pro-
gramme reports and accounts of the region and district 
in the custody of the malaria focal persons and account-
ing officers. Research and evaluation costs were not 
included. Costs were measured in Ghanaian Cedis (GHS) 
and pound sterling (GBP), depending on the currency of 
the original expenditure. Replacement costs of all capi-
tal items, such as vehicles, were obtained from the open 
market. Costs in GHS and GBP were converted to US$ 
according to Bank of Ghana’s average annual exchange 
rate for the year of the expenditure (US$1.00 equivalent 
to GHS3.74 in 2015).
Economic costs refer to opportunity costs and include 
costs of donated goods, such as AMOFAN medication or 
volunteered time spent on the intervention by volunteers 
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and caregivers. Data on time spent by volunteers and car-
egivers as part of the SMC intervention were obtained 
from two inter-related surveys. A cross-sectional survey 
of volunteers and caregivers participating in the SMC 
dosing exercises was undertaken purposively to deter-
mine their productivity losses. The data collection tool of 
volunteers covered: (1) demographics; and, (2) productiv-
ity loss (information on the time that volunteers spent on 
SMC training and dosing exercises, what they would have 
been doing if not working on SMC and the local farm 
wage rate for a day. Whilst the caregiver instrument was 
made up of: (1) demographics; (2) self-medication for 
malaria treatment; (3) insect bite preventive measures; 
(4) other household direct costs; and, (5) other household 
indirect costs (i.e., information on the time that caregiv-
ers spent on SMC dosing exercises and the amount of 
time caregivers had to wait at home for the dosing visit, 
what they would have been doing if not wait and engag-
ing in the SMC dosing).
Field data collection was carried out from 10–27 
November, 2015 in all 11 districts of the region. This 
was also the schedule period for the fourth round of 
dosing. Both volunteers and caregivers were verbally 
consented before the administration of the question-
naire. With the assistance of the district malaria focal-
persons, four or more volunteers per district were 
purposely selected for the interview depending on their 
availability, since the data collection period coincided 
with the fourth-round dosing and their farming season. 
Most volunteers and caregivers are primarily farm-
ers. After the interview with each volunteer, using the 
snowball approach, four or more caregivers who had 
dosed their children (3–59  months) were identified, 
consented and interviewed. A total of 122 volunteers 
and 512 caregivers were interviewed in all 11 dis-
tricts. Additionally, the research team used a checklist 
to observe and time-track some volunteers during the 
dosing exercise.
The Regional Health Administration (RHA) facilitated 
data collection in all 11 districts. The malaria focal-per-
sons in the 11 districts were interviewed on the resources 
they used in all four rounds of the implementation of 
SMC. The interview covered the following activities: (1) 
planning; (2) social mobilization; (3) training of health 
workers; (4) training of volunteers (community-based 
agents); (5) dosing exercise; (6) monitoring and supervi-
sion; (7) data capture; (8) pharmaco-vigilance; and, (9) 
post-SMC feedback/review meeting. In all these activi-
ties, the resources used in terms of recurrent and capi-
tal items were identified and enumerated. The available 
costs of these items were then collected from the malaria 
focal persons and the District Accounts Officer. For most 
of the capital items, their quantities and brand/type were 
ascertained and their replacement costs were obtained 
from the open market.
Data analysis
The data analyses covered cost analysis and estimation of 
the effectiveness of SMC dosing.
Cost analysis
Costing was undertaken from both provider perspec-
tive (which included provider-related costs incurred only 
on delivery of the intervention) and societal perspective 
(which included cost incurred on delivery of the inter-
vention, donations and the time and other expenses of 
caregivers). The analytic horizon was 4  months, which 
constituted the duration of the SMC implementation.
Financial and economic costs were analysed separately. 
Two categories of economic costs were considered in 
the analysis: direct costs and indirect costs of all inter-
vention activities. The direct costs were direct expenses 
incurred on programme activities and on capital and 
recurrent components. The capital costs included costs 
incurred on items with useful lives of more than 1 year, 
including vehicles, equipment, etc. The cost information 
was based on the entire duration of project implementa-
tion, from the planning phase to the end of the interven-
tion phase. All capital goods with an expected lifespan of 
more than 1 year were annualized using a discount rate 
of 3  % according to the guidelines of standard methods 
[24]. The lifespan of vehicles, such as pick-up trucks and 
motorbikes used in SMC activities, was estimated to be 5 
and 3 years, respectively, based on information received 
from the RHA Transport Manger. An average useful lifes-
pan of 3 years was assumed for office equipment, such as 
computer and printers. Other regional-level costs associ-
ated with SMC, such as planning, stakeholders meetings, 
monitoring and supervision, and post-SMC programme 
meetings were apportioned to the districts according to 
the number of sub-districts.
Recurrent costs included cost of items with useful lives 
of less than 1 year (e.g. medicine supplies, stationery sup-
plies, salaries and allowances of staff, etc.). The time of 
project personnel, health workers, volunteers and other 
staff involved in training were valued, using their gross 
monthly salaries, and added to the recurrent cost of the 
respective activity. The time of staff of Ghana Health 
Service and other stakeholders, who were directly com-
pensated for participation in the intervention, was val-
ued based on the standard Ghanaian Single Spine Salary 
structure as an economic cost. These allowances were 
based on a pre-determined market premium of each 
category of staff. The salary grades of all health workers 
involved in the SMC intervention were obtained from the 
Regional Administrator. The numbers of days worked on 
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the SMC intervention were obtained from the various 
districts’ malaria focal persons.
Data on indirect costs covered both volunteers’ and 
caregivers’ time and productivity losses (i.e., work days 
lost by engaging in SMC dosing). The total number of 
volunteers involved in the SMC programme was ascer-
tained for each district. The monetary value of work days 
lost was calculated by multiplying number of work days 
lost with the prevailing local agriculture wage rate (a the-
oretical measure of labour productivity) in the district. 
Summation of capital cost and recurrent cost constituted 
total financial or economic cost.
Measurement of SMC effectiveness
The number of children under-5 years dosed during the 
programme was obtained from the Regional Malaria 
Control Programme office, Upper West Regional Health 
Directorate for all four rounds of the intervention. The 
coverage for each district was used to estimate the num-
ber of fully dosed children under-5 years for each district. 
The measures of effect were:
Additional number of cases averted
Based on the prevalence of 31 % obtained from the SMC 
effectiveness study conducted by the Navrongo Health 
Research Centre, incidence of malaria during the trans-
mission season (when SMC was given) was estimated as 
350 per 1000 children, following the approach described 
in Cairns et  al. [27]. As described by Cairns et  al. [27], 
this is likely to be a conservative estimate of the inci-
dence rate in young children. The total case-load during 
the SMC period in Upper West region was estimated 
by applying this incidence rate to the total population 
of children under-5  years. Based on administrative cov-
erage of around 80, a conservative assumption of popu-
lation coverage of SMC of 60 % and efficacy of SMC in 
those who receive it was 80 % [27] were made. The bur-
den during the season, b, was therefore reduced by add-
ing together the (unaffected) burden in the 40 % who did 
not receive SMC, with the reduced burden in those who 
received SMC:
 This translates into a 48  % reduction in the estimated 
burden.
Additional number of all‑cause under‑five deaths averted
Mortality rate of 11.4 deaths per 1000 under-five popula-
tion for rural high transmission areas (estimated by Rowe 
et al. [28] and used in World Malaria Report 2008) was 
used to derive malaria deaths in the population. Then the 
SMC efficacy and administrative coverage were applied 
to the estimated deaths in the population to derive the 
b ∗ 0.4 + b ∗ 0.6 ∗ (1− 0.8) = b ∗ 0.52
number of deaths with SMC intervention. The difference 
between the estimated deaths with and without SMC 
constituted the number of deaths averted by SMC.
Estimating the incremental cost‑effectiveness of SMC
The SMC intervention was considered as an addition to 
existing health service. Thus, incremental cost-effective-
ness ratios (ICER) of SMC were calculated as the incre-
mental costs divided by the incremental effects, i.e., the 
additional effect (cases averted or deaths averted). A 
Microsoft Excel template was developed and used in cal-
culating costs and cost-effectiveness ratios.
Sensitivity analysis
Sensitivity analyses of ICERs were undertaken using 
varying key cost and effectiveness indicators, which had 
some degree of uncertainty. Key cost indicators varied, 
including medicine cost, discount rate, wage rate, pro-
tective efficacy, and deaths averted. Each was varied in 
turn in one-way sensitivity analyses. First, the cost of 
AMOFAN (SP/AQ) was inflated using the 2015 annual 
health consumer price index of 16.1  %. Second, a dis-
count rate of 5 % was used as the mid-value of the lower 
and upper values of 0 and 10 % [29]. Third, the national 
minimum wage rate of GHS7.00 per day was used to 
value all volunteer time in place of the local agricultural 
wage rate. Fourth, Tagbor et al. [30] estimated protective 
efficacy of 38.5  % was used in place of the pooled esti-
mate of 80 % efficacy. Again, actual administrative SMC 
coverage of 80  % was used in place of the conservative 
coverage of 60 % used in the analysis. Finally, to explore 
the importance of assumptions regarding estimated 
deaths averted using SMC, the constant mortality rate of 
4.5 deaths per 1000 population and ten deaths per 1000 
population [27] were used separately in the sensitivity 
analysis.
Results
A total of 148,104 children under-5  years of age in the 
Upper West Region were estimated as eligible for dos-
ing using regional census data. Out of this figure, 79.8 % 
received complete doses (i.e., four rounds).
Costs of SMC intervention
Financial costs
The total financial cost of the intervention in the region 
was US$1142,040.80. The minimum financial cost was 
US$61,571.06 in Dafiamma-Bussie-Issa (DBI) district 
and the maximum was US$253,308.45 in Sissala West 
district (Table 1). Recurrent cost constituted 95 % of the 
total financial cost. The dosing exercise and monitoring 
and supervision accounted for 27.7 and 27.6  %, respec-
tively, of the total financial cost. Data capture, training 
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(staff and volunteer) and pharmaco-vigilance accounted 
for 17.3, 11.9 and 7.2 %, respectively (Fig. 2).
Financial cost per fully dosed child
The (average) financial cost per fully dosed child (four 
rounds of SMC) for the Region was US$9.66 (95  % CI 
7.46–14.21), ranging from US$4.61 in Wa East to US$26.14 
in Sissala West (Fig. 3). Figure 4 shows the economies of 
scale of the dosing exercise where a higher percentage of 
fully dosed children leads to lower financial cost per fully 
dosed child, with the exception of Sissala West.
Economic costs of SMC
The total economic cost of the SMC intervention in the 
Region was estimated to be approximately US$7.96 mil-
lion from the societal perspective and US$2.66 million 
from the provider perspective (Table  1). For the soci-
etal costs, DBI recorded the least cost of US$389,192.38, 
whilst Wa Municipal recorded the highest economic cost 
of US$1175,496.28. For the provider costs, DBI recorded 
the least cost of US$133,891.17 whilst Wa East recorded 
the highest economic cost of US$347,268.45. Indirect 
costs accounted for about 74 % of the total societal costs 
and 24 % of the total provider costs. Recurrent cost con-
stituted 99 % of the total societal economic cost. Figure 5 
shows that by activity, the dosing exercise accounted for 
about 55 % of the total societal economic cost, followed 
by social mobilization (about 15 %) and monitoring and 
supervision (about 12  %). Training (of staff and volun-
teers) accounted for about 8 % of the total economic cost.
Effects of SMC intervention
Table  1 shows that the additional number of under-five 
malaria cases averted by the intervention in the Region 
was 24,881, representing 48 % of the total caseload with-
out SMC. The lowest number of additional cases averted 
was recorded in DBI (1155) and the highest was recorded 
in Wa East (3799). Additionally, Table 2 shows that a total 
number of 808 deaths was estimated to be averted by 
the intervention. The estimated lowest and highest child 
deaths averted were recorded in DBI (37) and Wa East 
(123) respectively.
Incremental cost effectiveness ratios (ICERs)
Table  1 shows that at the regional level, the economic 
cost per child dosed from the provider perspective was 
US$22.53 (95 % CI 21.08–28.06), with Wa West record-
ing the lowest (US$15.39) and Lambussie-Karni record-
ing the highest (US$33.26), respectively. From the 
societal perspective, the economic cost per child dosed 
was US$67.35 (95  % CI 63.56–77.86), ranging from 
US$46.37 in Wa East to US$92.74 in Wa Municipal. 
Table  1 further shows that the economic cost per addi-
tional case averted by the intervention from the provider 
perspective was US$107.06 (95 % CI 99.75–121.48), rang-
ing from US$83.25 in Jirapa to US$135.31 in Sissala West. 
From the societal perspective, the economic cost per 
additional case averted was US$319.96 (95 % CI: 284.23–
366.38), with the lowest recorded by Lawra (US$244.39) 
and highest by Wa Municipal (US$460.24).
The results show that the economic cost per additional 
child death averted by the intervention was US$3298.36 
(95  % CI 3073.26–3742.64), from the provider perspec-
tive and US$9858.02 (95 % CI 8757.11–11,288.08), from 
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was recorded by Jirapa (US$2655.04) and highest by Sis-
sala West (US$4168.78). From the societal perspective, 
the range of ICERs was US$14,179.87 and US$7529.68 
recorded by Wa Municipal and Lawra, respectively 
(Table 1).
Sensitivity analysis
The ICERs were sensitive to the mortality rates used in 
estimating deaths averted. For instance, the use of ten 
deaths per 1000 population [27] increased the economic 
cost per additional death averted by about 2.2 times. 
Similarly, the use of 4.5 deaths per 1000 population [27] 
increased the economic cost per additional death averted 
by about 6.3 times The ICERs were least sensitive to the 
discount rate, minimum wage and inflation in medicine 
cost. The ICERs were also sensitive to the protective effi-
cacy used; the use of 38.5 % protective efficacy found by 
Tagbor et al. [30] in the middle belt of Ghana increased 
the ICERs by about 1.1 times (from both provider and 
societal perspectives) by more than 100 % (Table 2).
Cost and cost‑effectiveness of other preventive malaria 
interventions
Studies have reported the financial cost per child cov-
ered by other interventions: US$9.90 (in 2015 $) in ITN 
campaigns in Ghana [12] and Uganda [13] and US$3.13 
(2015$) in IRS programmes in Kenya [20], Mozambique 
[18] and SSA [21], presented in Fig. 6. However, it is quite 
complicated to compare different preventive interven-
tions given the difference in the duration of efficacy of 
these interventions and the fact that the number of per-
sons protected is different—for instance SMC protects 
only one child while ITN and IRS could protect more 
than one child.
Studies have reported the economic cost (societal per-
spective) per death averted of other preventive malaria 
interventions. For example, IRS programmes in South 
Africa and Mozambique recorded an average ICER of 
US$4656.46 (in 2015$) per death averted [19]. Similarly, 
an ITN campaign in Ghana reported ICER of US$6739.20 
per death averted [12]. Again, direct comparison of these 
interventions is difficult (Fig. 7).
Discussion
The results show that the financial cost per child fully 
dosed (i.e., all four rounds of the survey) was US$9.66, 
implying that the financial cost per dosing one child per 
round is about US$3.25. Wa East recorded the lowest of 
US$4.61 and Sissala West recorded the highest finan-
cial cost per child dosed of US$26.14, although the dis-
trict’s record seems to be an outlier. The finding revealed 
some pattern between children fully dosed and financial 
cost per child fully dosed. This finding implies the exist-
ence of economies of scale, where completely dosing 
more children leads to a fall in the average cost of dos-
















Fig. 5 Economic cost profile by activity (%)
Table 1 Cost-effectiveness of smc programme in the upper 
west region
a Includes only provider-related costs incurred on delivery of the intervention
b Includes cost incurred on delivery of the intervention, donations and the 
valued time and other expenses of caregivers and volunteers
Item Region
Target population (children under 
5 years)
148,104.00
Number of fully dosed children 118,208.00
Cost of SMC programme (US$, 2015 prices)
 Total financial cost 1142,040.80
 Financial cost per fully dosed 
child
9.66 (95 % CI 7.46–14.21)
 Economic cost (provider perspec-
tive)
2663,697.18
 Economic cost (societal perspec-
tive)
7961,153.27
Effect of SMC programme
 Additional number of cases 
averted
24,881
 Additional number of child 
deaths averted
808
Cost-effectiveness ratios (ICERs) (US$, 2015 prices)
 Provider perspectivea
  Economic cost per fully dosed 
child
22.53 (95 % CI 21.08–28.06)
  Economic cost per additional 
case averted
107.06 (95 % CI 99.75–121.48)
  Economic cost per additional 
child death averted
3298.36 (95 % CI 3073.26–3742.64)
 Societal perspectiveb
  Economic cost per fully dosed 
child
67.35 (95 % CI 63.56–77.86)
  Economic cost per additional 
case averted
319.96 (95 % CI 284.23–366.38)
  Economic cost per additional 
child death averted
9858.02 (95 % CI 8757.11–11,288.08)
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as a motivation for districts to cover as many children 
as possible in order to reduce their average costs. The 
financial cost per child fully dosed in this study compares 
with similar findings on ITN campaigns [12, 13]. How-
ever, lower estimates are reported for IRS [18, 20, 21]. 
Although the cost of medicines for SMC is expected to be 
higher than that of ITNs, the average cost of implement-
ing SMC is within the range of other preventive malaria 
interventions. For financial cost, the main cost drivers 
were the dosing exercise and monitoring and supervision 
(both of which account for about an equal share of the 
total cost), and data capture.
The study further shows that the economic costs of the 
SMC intervention were about US$7.96 million from the 
societal perspective and US$2.66 million from the pro-
vider perspective, implying that if only costs from the 
provider perspective are considered, total costs would be 
less by about two-thirds. The bulk of the difference was 
due to valued caregiver productive losses due to par-
ticipation in the intervention. The total economic cost 
of the intervention ranges from US$389,192.38 (DBI) to 
US$1175,496.28 (Wa Municipal) for societal costs and 
US$133,891.17 (DBI) to US$347,268.45 (Wa East) for 
provider perspective costs. The differences in these costs 
Table 2 Sensitivity analysis results









Base estimates Base case scenario 107.06 3298.38 319.96 9858.02
Medicine cost Application of 16.1 % 
inflation rate
112.55 3467.77 325.46 10,027.43
Discount rate Increasing the discount 
rate from 3 to 5 %
107.24 3304.16 320.15 9863.81
National min. wage 
rate
Use of national daily 
minimum wage rate 
of GHS7 rather than 
agric wage of GHS 
11.36
97.33 2328.26 228.48 6958.60
Mortality rate 10 deaths per 1000 
population
107.60 2998.65 319.96 7039.40
Mortality rate 4.5 deaths per 1000 
population
107.60 6853.74 319.96 20,484.19
SMC coverage Increase in SMC admin-
istrative coverage 
from 60 to 80 %
107.60 10,654.79 319.96 31,996.31
SMC protective 
efficacy
Decrease in protective 
efficacy from 80 to 
38.5 %





















































































































Fig. 6 Financial cost per child by other preventive interventions
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across districts seem to stem from the land area covered 
as well as the number of children, volunteers and caregiv-
ers in each district. Districts covering smaller land area 
and smaller population of number of children, caregivers 
and volunteers tend to record lower economic costs.
For economic costs (societal perspective), the main cost 
drivers were the dosing exercise (which accounts for more 
than half of the total), social mobilization and monitor-
ing and supervision. These three activities used significant 
volunteer and caregiver time, confirming the important 
role that caregivers play in any community-based inter-
vention, as these people are not remunerated. This is also 
confirmed by the result that indirect costs accounted for 
about three-quarters (i.e., 74 %) of the total economic cost 
from the societal perspective but only a quarter of the 
total economic cost from the provider perspective. While 
arguing that some compensation for caregivers may seem 
uneconomical, it is important to acknowledge their role 
and, perhaps, implement interventions by targeting their 
availability. For instance, the dosing exercise could be held 
in the evenings, when caregivers do not have to sacrifice 
productive time to be involved in the activity, which could 
significantly reduce the productivity loses. The dosing 
exercise, social mobilization, and monitoring and supervi-
sion also benefitted from donations from other agencies. 
For instance, in most districts, social mobilization and 
monitoring and supervision benefited from use of vehicles 
and equipment from other agencies within the districts 
but outside the health system. These were accounted for 
in estimating societal costs.
This study has estimated the additional number of 
under-five malaria cases averted in the region to be 
24,881. This represents a 48  % reduction in malaria 
caseload due to SMC. Given the burden that malaria 
places on this vulnerable group, the SMC intervention 
has led to considerable reduction in the burden, mainly 
morbidity. It is difficult to compare this outcome to 
other interventions in Ghana, especially the ITN mass 
distribution campaign because that campaign used a 
different outcome indicator (i.e., number of children 
using an ITN) and targeted a different population size. 
However, studies have reported that ITN and IRS have 
protective efficacy of 50–60  % [27, 31] while SMC is 
reported to have protective efficacy of up to 80 % with 
full dose [27].
Further, this study has estimated the additional deaths 
averted in the region due to SMC to be 808. A study on 
ITN distribution and hanging in Ghana [12] reported 
additional number of deaths averted by region to range 
between 445 and 637. However, given the difference in 
the total population covered by the two interventions, it 
is difficult to directly compared these estimates.
The study finds that economic cost per child fully 
dosed was US$22.53 from the provider perspective and 
US$67.35 from the societal perspective. Further, the eco-
nomic cost per additional case averted was US$107.06 
from the provider perspective and US$319.96 from 
societal perspective. The study also finds that the SMC 
intervention averts one additional under-five death at 
cost of US$3298.36 from the provider perspective and 
US$9858.02 from the societal perspective. There are var-
ied opinions regarding which thresholds to use in judg-
ing the cost-effectiveness of health interventions and 
these are extensively discussed in Culyer [32]. However, 
in line with other studies [24], we use the WHO-recom-
mended thresholds—that health interventions are highly 
cost-effective if ICER is less than GDP per capita and 
cost-effective if ICER falls within one to three times GDP 
per capita. The Ghana Statistical Service [33] estimates 
Ghana’s 2015 GDP per capita to be US$1339.00. Thus, 
SMC intervention is highly cost-effective in terms of eco-
nomic cost per additional case averted at the districts 
































Fig. 7 Economic cost per additional death averted
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In terms of cost per additional deaths averted, the 
SMC intervention is cost-effective at regional level and 
at districts (except for Sissala West and Wa Municipal) 
from the provider perspective. However, the interven-
tion is not cost-effective from the societal perspective 
as the ICERs were higher than US$4017.00. Although 
the societal perspective is important for assessing cost-
effectiveness of interventions that use substantial com-
munity resources, considering that many time-related 
community resources, especially from caregivers who 
hold the health of their children above their time, tend 
to be community contributions for which remunera-
tions are not expected (although they come with oppor-
tunity costs), it may not be out-of-place to consider 
the provider perspective in deciding the worth of a 
programme.
The ICERs were sensitive to the choice of mortality rate 
used. Understandably, it could be argued that the mortality 
rate of 11.36 deaths per 1000 population used to estimate 
the ICERs in this study is an old estimate. However, updat-
ing that estimate requires collecting large, context-specific 
data, which can be a complex exercise. Besides, that mor-
tality rate was the basis for estimating malaria mortality 
presented in some World Malaria Reports (e.g., in 2008) 
and other studies [27]. Further, although a study in Ghana 
found protective efficacy of 38.5  %, the Ashanti Region 
where that study was conducted has different climatic 
conditions compared to the Upper West Region. Con-
sequently, the rate of 80  % protective efficacy is best for 
this study given that the Upper West Region is among the 
Regions with highest burden of malaria in Ghana (37.8 %) 
compared with 16.6 % prevalence in the Ashanti Region.
The cost per additional death averted (from societal 
perspective) for this study is higher compared to those 
of other studies in evaluating other preventive malaria 
interventions. However, the cost per additional death 
averted from provider perspective and economic cost 
per additional case averted estimated from this study are 
comparable to those of the other studies.
The study team observed some constraints to the 
SMC implementation approach used. For example, the 
implementation of the exercise during the farming sea-
son makes it difficult for caregivers to fully participate 
and this could affect the outcome of the exercise. How-
ever, as stated elsewhere in this paper, implementation 
of the SMC intervention is recommended for the season. 
Future dosing exercises may be scheduled to allow vol-
unteers to visit households in the evening during which 
time caregivers would have returned from the farm. This 
could improve their participation and enhance outcomes, 
but also reduce their productive losses to caregivers. 
Further, the use of AMOFAN tablets, which volunteers 
find difficult to crash, posed some challenges to the 
administration of the medicine. Future exercises could 
consider using dispersible medicine.
Some limitations of the study are worthy to note. First, 
the estimation of effects of the intervention had to rely on 
parameters from the literature (although these were com-
bined with prevalence obtained locally) because data on 
number of cases and deaths averted were not available. 
Thus, the rates used may influence the true impact of SMC 
in Ghana. Second, it was assumed that the effects of the 
intervention were observed only in children who received 
the complete course (i.e., four course/fully dosed). Thus, 
the standard 80  % protective efficacy was applied to the 
number of children who received all four courses. How-
ever, it has been shown [27] that even in children who 
receive three courses, protective efficacy could be up to 
65 %. These effects could not be added to the model as the 
data available at the study site did not distinguish between 
the number of children who received three doses but could 
not receive four. Thus, the ICERs would be different from 
the estimated results if the 65  % protective efficacy had 
been calculated for those who received three doses and 
added to the 80 % efficacy of four doses.
Conclusions
The financial cost per the SMC intervention delivered 
to a child under-five was US$9.66. Due to economies of 
scale, it is possible to deliver the intervention to more 
children at less than US$9.66. This represents a good use 
of society’s money and favours scaling-up of the inter-
vention. The economic cost per additional case averted 
of US$107.06 and US$319.96 also represents value-for-
money (i.e., cost-effective). The findings of this study 
show that the SMC intervention is economically ben-
eficial in reducing morbidity in children under-5  years 
and presents a viable approach to improving under-five 
health in Ghana. Therefore, the SMC intervention is rec-
ommended for scaling-up as it represents a good use of 
economic resources from the provider perspective.
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